

Heather J Adam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5098923/publications.pdf>

Version: 2024-02-01

63
papers

1,945
citations

331670

21
h-index

265206

42
g-index

64
all docs

64
docs citations

64
times ranked

2293
citing authors

#	ARTICLE	IF	CITATIONS
1	Imipenemâ€“Relebactam and Meropenemâ€“Vaborbactam: Two Novel Carbapenem-Î²-Lactamase Inhibitor Combinations. <i>Drugs</i> , 2018, 78, 65-98.	10.9	291
2	Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. <i>Drugs</i> , 2019, 79, 271-289.	10.9	274
3	Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. <i>Drugs</i> , 2016, 76, 567-588.	10.9	199
4	Serotype distribution of invasive <i>Streptococcus pneumoniae</i> in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010â€“2012. <i>Canadian Journal of Microbiology</i> , 2013, 59, 778-788.	1.7	99
5	Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant <i>Streptococcus pneumoniae</i> in Canada, 1997â€“2006. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 82-85.	2.5	68
6	Characterization of MDR and XDR <i>Streptococcus pneumoniae</i> in Canada, 2007â€“13. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2199-2202.	3.0	65
7	In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014â€“2015. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 55-62.	1.8	60
8	Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. <i>Drugs</i> , 2020, 80, 285-313.	10.9	60
9	Evaluation of three MALDI-TOF mass spectrometry libraries for the identification of filamentous fungi in three clinical microbiology laboratories in Manitoba, Canada. <i>Mycoses</i> , 2018, 61, 743-753.	4.0	50
10	Analysis of multidrug resistance in the predominant <i>Streptococcus pneumoniae</i> serotypes in Canada: the SAVE study, 2011â€“15. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, vii12-vii19.	3.0	48
11	42936 pathogens from Canadian hospitals: 10 years of results (2007â€“16) from the CANWARD surveillance study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, iv5-iv21.	3.0	43
12	Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia. <i>Drugs</i> , 2016, 76, 1737-1757.	10.9	38
13	Antimicrobial susceptibility of 2906 <i>Pseudomonas aeruginosa</i> clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: Results of the Canadian Ward surveillance study (CANWARD), 2008â€“2015. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 87, 60-63.	1.8	36
14	Dramatic rise in the proportion of ESBL-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, iv64-iv71.	3.0	36
15	In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 97, 115012.	1.8	36
16	Assessment of multidrug resistance, clonality and virulence in non-PCV-13 <i>Streptococcus pneumoniae</i> serotypes in Canada, 2011-13. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1960-4.	3.0	31
17	Invasive <i>Streptococcus pneumoniae</i> in Canada, 2011â€“2014: Characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F. <i>Vaccine</i> , 2016, 34, 2527-2530.	3.8	28
18	Molecular characterization of predominant <i>Streptococcus pneumoniae</i> serotypes causing invasive infections in Canada: the SAVE study, 2011â€“15. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, vii20-vii31.	3.0	27

#	ARTICLE	IF	CITATIONS
19	Species distribution and antifungal susceptibility of invasive <i>Candida</i> isolates from Canadian hospitals: results of the CANWARD 2011–16 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, iv48-iv54.	3.0	27
20	Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 645-653.	3.0	26
21	Frequency of MCR-1-mediated colistin resistance among <i>Escherichia coli</i> clinical isolates obtained from patients in Canadian hospitals (CANWARD 2008-2015). <i>CMAJ Open</i> , 2016, 4, E641-E645.	2.4	24
22	Comparison of commercial assays and laboratory developed tests for detection of SARS-CoV-2. <i>Journal of Virological Methods</i> , 2020, 285, 113970.	2.1	24
23	PCR ribotyping and antimicrobial susceptibility testing of isolates of <i>Clostridium difficile</i> cultured from toxin-positive diarrheal stools of patients receiving medical care in Canadian hospitals: the Canadian <i>Clostridium difficile</i> Surveillance Study (CAN-DIFF) 2013–2015. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 105-111.	1.8	23
24	Characterization of carbapenem-resistant and XDR <i>Pseudomonas aeruginosa</i> in Canada: results of the CANWARD 2007–16 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, iv32-iv38.	3.0	23
25	In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible <i>Pseudomonas aeruginosa</i> clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008–16. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 703-708.	3.0	21
26	Comparison of antimicrobial resistance patterns in <i>Streptococcus pneumoniae</i> from respiratory and blood cultures in Canadian hospitals from 2007–16. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, iv39-iv47.	3.0	21
27	In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of <i>Escherichia coli</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	20
28	Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. <i>Drugs</i> , 2021, 81, 233-256.	10.9	20
29	<i>In Vitro</i> Activity of Plazomicin against Gram-Negative and Gram-Positive Bacterial Pathogens Isolated from Patients in Canadian Hospitals from 2013 to 2017 as Part of the CANWARD Surveillance Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	19
30	Antimicrobial susceptibility testing of invasive isolates of <i>Streptococcus pneumoniae</i> from Canadian patients: the SAVE study, 2011–15. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, vii5-vii11.	3.0	17
31	Antimicrobial susceptibility of <i>Clostridioides difficile</i> isolated from diarrhoeal stool specimens of Canadian patients: summary of results from the Canadian <i>Clostridioides difficile</i> (CAN-DIFF) surveillance study from 2013 to 2017. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1824-1832.	3.0	15
32	In vitro susceptibility of urinary <i>Escherichia coli</i> isolates to first- and second-line empirically prescribed oral antimicrobials: CANWARD surveillance study results for Canadian outpatients, 2007–2016. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 62-68.	2.5	14
33	Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria. <i>Drugs</i> , 2022, 82, 533-557.	10.9	12
34	Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum β -lactamase (ESBL)-, KPC- or NDM-producing <i>Escherichia coli</i> with reduced susceptibility or resistance to ertapenem using an in vitro model. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2448-2452.	3.0	10
35	<i>In Vitro</i> Activity of Ceftazidime-Avibactam against 338 Molecularly Characterized Gentamicin-Nonsusceptible Gram-Negative Clinical Isolates Obtained from Patients in Canadian Hospitals. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3623-3626.	3.2	10
36	In vitro activity of Oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2015. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 87, 349-356.	1.8	10

#	ARTICLE	IF	CITATIONS
37	<i>In vitro</i> activity and resistance rates of topical antimicrobials fusidic acid, mupirocin and ozenoxacin against skin and soft tissue infection pathogens obtained across Canada (CANWARD) Tj ETQq1 1 0.784314 rgBT1/Overlook		
38	Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007–19. JAC-Antimicrobial Resistance, 2022, 4, dlab197.	2.1	10
39	<i>In Vitro</i> Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019. Microbiology Spectrum, 2022, 10, .	3.0	9
40	Susceptibility of Clinical Isolates of Escherichia coli to Fosfomycin as Measured by Four <i>In Vitro</i> Testing Methods. Journal of Clinical Microbiology, 2020, 58, .	3.9	8
41	ESBL-positive <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> isolates from across Canada: CANWARD surveillance study, 2007–18. Journal of Antimicrobial Chemotherapy, 2021, 76, 2815-2824.	3.0	8
42	In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016-2019. Diagnostic Microbiology and Infectious Disease, 2021, 101, 115418.	1.8	8
43	Comparison of PCV-10 and PCV-13 vaccine coverage for invasive pneumococcal isolates obtained across Canadian geographic regions, SAVE 2011 to 2017. Diagnostic Microbiology and Infectious Disease, 2021, 99, 115282.	1.8	7
44	Use of Fosfomycin Etest To Determine <i>In Vitro</i> Susceptibility of Clinical Isolates of <i>Enterobacterales</i> Other than <i>Escherichia coli</i> , Nonfermenting Gram-Negative Bacilli, and Gram-Positive Cocci. Journal of Clinical Microbiology, 2021, 59, e0163521.	3.9	7
45	Invasive pneumococcal disease caused by serotypes 22F and 33F in Canada: the SAVE study 2011–2018. Diagnostic Microbiology and Infectious Disease, 2021, 101, 115447.	1.8	7
46	Evaluation of MRSA Select ⁺ Chromogenic Medium for the Early Detection of Methicillin-Resistant <i>Staphylococcus aureus</i> from Blood Cultures. Canadian Journal of Infectious Diseases and Medical Microbiology, 2013, 24, e113-e116.	1.9	6
47	Pharmacodynamic activity of fosfomycin simulating urinary concentrations achieved after a single 3-g oral dose versus <i>Escherichia coli</i> using an in vitro model. Diagnostic Microbiology and Infectious Disease, 2017, 88, 271-275.	1.8	6
48	Whole genome characterization of <i>Streptococcus pneumoniae</i> from respiratory and blood cultures collected from Canadian hospitals before and after PCV-13 implementation in Canada: Focus on serotypes 22F and 33F from CANWARD 2007–2018. Vaccine, 2021, 39, 5474-5483.	3.8	6
49	Frequency of 16S ribosomal RNA methyltransferase detection among <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> clinical isolates obtained from patients in Canadian hospitals (CANWARD, 2013–2017). Diagnostic Microbiology and Infectious Disease, 2019, 94, 199-201.	1.8	4
50	Comparison of phenotypic antimicrobial susceptibility testing results and WGS-derived genotypic resistance profiles for a cohort of ESBL-producing <i>Escherichia coli</i> collected from Canadian hospitals: CANWARD 2007–18. Journal of Antimicrobial Chemotherapy, 2021, 76, 2825-2832.	3.0	4
51	Clinical Metagenomics Is Increasingly Accurate and Affordable to Detect Enteric Bacterial Pathogens in Stool. Microorganisms, 2022, 10, 441.	3.6	4
52	Ten years of the CANWARD Study (2007–16). Journal of Antimicrobial Chemotherapy, 2019, 74, iv2-iv4.	3.0	3
53	Failure of a multiplex polymerase chain reaction assay to detect IMP-27 in a clinical isolate of <i>Morganella morganii</i> . Diagnostic Microbiology and Infectious Disease, 2018, 92, 194-195.	1.8	2
54	Introduction to the SAVE study (2011–15): <i>Streptococcus pneumoniae</i> serotyping and antimicrobial susceptibility: Assessment for Vaccine Efficacy in Canada after the introduction of PCV-13. Journal of Antimicrobial Chemotherapy, 2018, 73, vii2-vii4.	3.0	2

#	ARTICLE	IF	CITATIONS
55	Fosfomycin resistance mediated by fos genes remains rare among extended-spectrum beta-lactamase-producing <i>Escherichia coli</i> clinical isolates recovered from the urine of patients evaluated at Canadian hospitals (CANWARD, 2007–2017). <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114962.	1.8	2
56	PCV-15 and PPSV-23 coverage of invasive and respiratory tract <i>Streptococcus pneumoniae</i> , including MDR and XDR isolates: CANWARD 2007–20. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1444-1451.	3.0	2
57	Cefotaxime susceptibility should not be used to predict ceftriaxone susceptibility among <i>Klebsiella oxytoca</i> clinical isolates. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 21, 270-271.	2.2	1
58	Evaluation of the Hologic Aptima Combo 2 Assay for Detection of <i>Neisseria gonorrhoeae</i> from Joint Fluid Specimens. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0253021.	3.9	1
59	254 In Vitro Activity of Ceftazidime in Combination with Avibactam vs 1825 <i>Pseudomonas aeruginosa</i> Clinical Isolates Obtained from across Canada as Part of the CANWARD Study, 2009-2013. <i>Open Forum Infectious Diseases</i> , 2014, 1, S109-S109.	0.9	0
60	In Vitro Activity of Newer Antimicrobials and Relevant Comparators Vs. 349 <i>Stenotrophomonas maltophilia</i> Clinical Isolates Obtained from Patients in Canadian Hospitals (CANWARD, 2011–2016). <i>Open Forum Infectious Diseases</i> , 2017, 4, S367-S368.	0.9	0
61	In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible <i>Pseudomonas aeruginosa</i> Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016. <i>Open Forum Infectious Diseases</i> , 2017, 4, S372-S372.	0.9	0
62	2383. In Vitro Activity of Ceftolozane–Tazobactam in Comparison With Ceftazidime–Avibactam vs. Antimicrobial Non-Susceptible <i>Pseudomonas aeruginosa</i> Clinical Isolates, Including Multidrug-Resistant and Extensively Drug-Resistant Subsets: CANWARD, 2007–2017. <i>Open Forum Infectious Diseases</i> , 2018, 5, S710-S710.	0.9	0
63	In vitro susceptibility of common bacterial pathogens causing respiratory tract infections in Canada to lefamulin, a new pleuromutilin. <i>Jammi</i> , 2021, 6, 149-162.	0.5	0